chrisvoncsefalvay/vaers-outcomes huggingface dataset:
little pimples all over her body; rash at the site of injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the site of injection) and ACNE (little pimples all over her body) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced VACCINATION SITE RASH (rash at the site of injection). On an unknown date, the patient experienced ACNE (little pimples all over her body). At the time of the report, VACCINATION SITE RASH (rash at the site of injection) had not resolved and ACNE (little pimples all over her body) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medication was available. No Treatment Medication was available.   Reporter did not allow further contact
Worsening and Increase in Premature Ventricular Contractions, chest pain, heart palpitations, and exhaustion approximately  5 days after receiving 2nd dose (5/24/201). Symptoms persistent and recurrent daily to present day.
my father started having shortness of breath within a couple of hours of having the second pfizer covid vaccine. The next day, I took him to Medical Center ER. Since then he has been to the cardiologist and pulmonoloigst. The SOB continues, however, it comes and goes and has gotten less severe.
This spontaneous report was received from a register nurse via a company representative and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. The nurse reported that on an unknown date, the patient was inadvertently administered a dose of PREVNAR 13 (dose, route, lot number and expiration date were not reported) for prophylaxis, instead of an intended dose of PNEUMOVAX23 (dose, route, lot number and expiration date were not reported). The reason for the error was unknown. No adverse effect reported. Additional information has been requested.
Headache, joint pain, aches all over, fatigue, sweats, and chills for about 24 hours.
Information has been received from a physician concerning a female 4 to 6 years of age who was vaccinated with a dose of MMR II/V vaccine. Subsequently the patient experienced "what looked like cellulitis in the thigh". It was reported that the patient may have been treated with "a little Ibuprofen and a little cold pack". Additional information has been requested.
Crying non-stop from 06:00 until 13:15, 4/13/2000.
Initial report received on 18 November 2009 from a health care professional. A 75 year old female patient with no illness at the time of vaccination developed a racing heart rate, an increase in blood pressure, and facial flushing two to two and a half hours (approximately 1:00 PM) after receiving FLUZONE (lot number unknown) on 18 November 2009 at 11:00 AM. The patient reported receiving the vaccine every year since 1995. Concomitant therapy included LIPITOR, vitamins, fish oil, calcium, CLINORIL, and NIZORAL. It was reported that the patient had a doctor's visit, however a date was not provided. Recovery status was unknown. List of Documents held by Sender: none.
Just under 24 hours after receiving the vaccine, I developed a low grade temp that fluctuated to 99.8 for 3 days, body aches, felt somewhat unwell and  fatigued. That all remitted at about 4 full days after receiving the vaccine. I did have arm aching within hours as well.
Patient was given an half dose (0.25mL) of Moderna instead of a pediatric dose of Pfizer.
Pt received vaccine in privacy room and walked to front lobby to wait 15minutes as recommended. After cleaning room, I went to check on pt and was bent over with elbows on her knees. Pt said she was feeling dizzy. After a few minutes, pt asked to use the restroom. On the way to the restroom, pt got light headed and partially collapsed (she was caught and gently lowered to the ground). Pt was sweating and light-headed. Given ice pack and put in chair to rest and given a drink of water. After about 15 minutes, pt now says she is feeling fine and back to normal and able to walk on her own.
On 5/3/2021 was found to be unresponsive with low BP and slow heart rate.  911 was initiated and CPR started.  Resident was admitted to Hospital with diagnosis of respiratory failure
This case was reported by a other health professional via call center representative and described the occurrence of shoulder pain in a 54-year-old male patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX (1st dose received on an unknown date, no reaction). On 15th October 2018, the patient received the 2nd dose of SHINGRIX. On 16th October 2018, 1 days after receiving SHINGRIX, the patient experienced shoulder pain, fever and pain in arm. On an unknown date, the outcome of the shoulder pain, fever and pain in arm were unknown. It was unknown if the reporter considered the shoulder pain, fever and pain in arm to be related to SHINGRIX. Additional details were provided as follows: The patient experienced pain in his shoulder and arm and a fever the following day of vaccination. The healthcare professional had no lot or expiry date.
Narrative:  Patient reported rash and itching following administration of 1st dose of Shingrix vaccine. No interventions were reported.
A vial of Janssen COVID-19 vaccine was placed where open Pfizer would typically be placed and RPh withdrew 0.3 ml of Janssen vaccine instead of Pfizer. This dose was administered to patient and the mistake was realized after patient left pharmacy. Patient has been followed up with 3 hours post event by RPh and is asymptomatic.
Benadryl given at COVID vaccine area. To ED received Ativan, Decadron, Pepcid, Benadryl, and 2L NS.
pericarditis, chest pain and nausea, treated with anti-inflammatories and anti-nausea medicines
Pt had AFIB and was on ELIQUIS 2.5 mg BID. He began to bleed, a lot. We stopped DOAC, disussed possibility pt might die form blood clot without the DOAC. He had vaccine  after stopping DOAC (stopped DOAC 2/24/21). On 3/8 he had the Janssen Vaccine. On  3/15 he awoke w weakness, inability to speak. Transferred to hospital where he was diagnosed w having major stroke, admitted to hospital. They decided NOT to use anticoagulant because he had too great a risk of bleeding.
Patient had the HPV vaccine in April 2021 and mom states that her child has not been the same since.  She suffered from a high grade temperature of >102 for more than 7 days and she had nausea and headaches which have persisted to this day.  Note the fever resolved after one week but the other symptoms persisted
Sudden death. He was perfectly healthy. This vaccination is the only thing I can think of that would have caused this.  Everything else in his life was normal, the same.
7/27/11 seizure #1 5:30AM - Emergency Room seizure lasted 1 minute, then 30 minutes to become alert. 8/10/11 #2 8:00AM - seizure duration 30 seconds, 1/2 hr to recover. 8/29/11 #3 4:34AM - 1 minute seizure, 1 hour to recover, stopped breathing, turned red. KEPPRA 500 XR.
12/10 J&J booster 12/11 fever, back/neck pain 12/13 interval worsening + diaphoresis  12/14 persistent symptoms with interval improvement + decreased ROM of the BLEs due to soreness/muscle tightness, diffuse arthralgia  12/15 bilateral foot and hand edema, severe diffuse arthralgia with neuralgia/paraesthesia localized to bilateral, medial ankles and just proximal to the ankles 12/16 + rash overlying area of neuropathy for which pt took ibuprofen 800mg and Benadryl with no relief. Presented to the ED due to rash/discomfort ascending 1/4 up the legs. (Symmetrical, medial, BLEs)  Presented to the ED late night 12/16: afebrile, BP 71/50, HR 56. Found to have RBBB. Admitted for BLE vasculitis, hypotension, and AKI.  IVF resuscitation. Admitted early morning 12/17 with interval worsening/ascension of vasculitis. Derm, Nephro, ID consulted. ID recommended reporting to VAERS at this time.  As of this morning, pt remains afebrile, requiring prn analgesics. Work-up per Derm, Nephro, and ID recommendations as stated in #19.  Pt is still admitted at this time. I am now off service and will update further clinical course and workup at a later date.
101 fever, aches, chills, headache.  Followed the next day diarrhea the following day.
Gastroenteritis Rotavirus. A mother reported her child received her 1st dose of Prevnar on 2/22/01. Subsequently, she developed diarrhea. a stool sample was positive for rotavirus. No further information was available at the date of this report. This pt developed a fever and diarrhea following receipt of her second dose of Prevnar.
Test: Covid test Date: 2Jun2022 Result: positive; Test: Covid test Date: 2Jun2022 Result: positive; This is a spontaneous report received from contactable reporter(s) (Other HCP).  A 71-year-old female patient received BNT162b2 (BNT162B2), on 05Feb2021 as dose 1, 0.3 ml single (Lot number: EM9810), on 26Feb2021 as dose 2, 0.3 ml single (Lot number: EN6200) and on 08Nov2021 as dose 3 (booster), 0.3 ml single (Lot number: FH8028) at the age of 71 years for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ASPIRIN [ACETYLSALICYLIC ACID]; CARDIZEM CD; TAMBOCOR; ZOLOFT; MUCINEX DM; TESSALON PERLE. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 02Jun2022, outcome "unknown" and all described as "Test: Covid test Date: 2Jun2022 Result: positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (02Jun2022) Positive, notes: Result: positive; Unit: Not Provided.  Clinical course: Patient tested positive for Covid after receiving three doses of vaccine. Had Covid test on 02Jun2022 resulted positive and had received concomitant medications included Multivitamin.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and vaccination failure, Covid 19 cannot be completely excluded.
Patient developed Polymyalgia rheumatica in July of 2021. There is good chance it isn't related to the vaccine, but wanted to document it. She is currently under treatment on steroids and actually just started the  steroid regimen on December 21st, 2021. The diagnosis was delayed for a few months. She is currently doing well, but in treatment.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Headache-Medium, Systemic: Hypotension-Medium, Systemic: Nausea-Medium, Systemic: Vomiting-Medium
COVID-19; More tired than usual; Mild headaches; Stuffy nose; A spontaneous report was received from a Consumer concerning a 64 years old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced COVID-19, Fatigue, Headache and Nasal congestion.  The patient's medical history was not provided. Relevant concomitant medications were reported as supplements, vitamin D and B, fish oil, Calcium, Multivitamin, CoQ 10 and red yeast rice.  On 13-JAN-2021, prior to the onset of the events, the patient received their first dose of two planned dose of mRNA-1273 (lot/batch: 037K20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection. On 15 JAN 2021, the patient experienced Fatigue, Headache and Nasal congestion. On 20-JAN-2021, the patient confirmed COVID-19. These events are medically significant.  Laboratory details were provided as COVID-19 test and the result was positive. Treatment information was provided as an aspirin a day to prevent blood clothing.  Action taken with mRNA-1273 in response to the events was unknown.  At the time of this report, the outcome of the event's COVID-19, Fatigue, Headache and Nasal congestion was considered as unknown.
high fever after getting the second dose; body aches after getting the second dose; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (high fever after getting the second dose) and MYALGIA (body aches after getting the second dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (high fever after getting the second dose) and MYALGIA (body aches after getting the second dose). At the time of the report, PYREXIA (high fever after getting the second dose) and MYALGIA (body aches after getting the second dose) outcome was unknown.            Treatment information was not provided. Concomitant medications were not reported.  Action taken with the mRNA-1273 in response to the event is not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 19-May-2021: Additional information added on 19-May-2021 as no new information.
body is screaming overdose; may have been given a full 0.5ml as a booster/body is screaming overdose; Down for nine days; This spontaneous case was reported by an other health care professional and describes the occurrence of SCREAMING (body is screaming overdose), DEPRESSED MOOD (Down for nine days) and OVERDOSE (may have been given a full 0.5ml as a booster/body is screaming overdose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On an unknown date, the patient experienced SCREAMING (body is screaming overdose), DEPRESSED MOOD (Down for nine days) and OVERDOSE (may have been given a full 0.5ml as a booster/body is screaming overdose). At the time of the report, SCREAMING (body is screaming overdose) outcome was unknown and DEPRESSED MOOD (Down for nine days) and OVERDOSE (may have been given a full 0.5ml as a booster/body is screaming overdose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was reported.  It was reported that patient had no problem with first two shots (doses).
Initial report received on 21 November 2009 from a company representative, who received the original report from a consumer. A female patient (demographics not reported) had received on 20 November 2009 a dose of H1N1 (lot number not reported) along with a steroid shot for her arthritic left hip pain. The patient reported she has had problems with her hip for quite a while. At an unspecified amount of time after receiving the vaccination, the patient reported that she felt like she had been hit by a truck. It was not reported whether the patient had received any medical evaluation or treatment. Follow-up information provided by the patient on 09 December 2009 via telephone call to the patient. The patient reported she had felt "generally unwell" for 3-4 days after receiving the H1N1 vaccine, but symptoms had spontaneously resolved without treatment or physician visit. The event was updated with this new information. The patient requested that she not be contacted again regarding this event. No further information is expected. Documents held by sender: None.
Mother and child presented to the Health Dept 8-31-2011 after child received vaccines on 8-29-11. Mom reports child had redness and swelling in left arm just below varicella site. Swollen, red area above elbow and in mid area. Counseled re reactions to expect following following Dtap and varicella. Provided VIS and counseled.
This spontaneous report has been received from a registered nurse referring to a patient of an unknown age and gender. The patient's medical history, drug and allergy history and current conditions were not reported. It was reported that on an unknown date, a patient was vaccinated with an improperly stored dose of PROQUAD lot # M031567 and expiration date of 24-DEC-2017. The patient's concomitant therapies were not provided. The vaccine was stored at a temperature of 6° Fahrenheit (F) during a time frame of 14 hours and 55 minutes with no previous temperature excursions. No adverse events were reported. Additional information has been requested.
Information has been received from a female consumer (age unknown), who, on an unspecified date, was vaccinated with a dose of PNEUMOVAX (manufacturer unknown). Concomitant vaccination included influenza virus vaccine (unspecified). Other concomitant therapy included SYNVISC. Subsequently, on an unspecified date, the patient experienced sweating, difficulty breathing, and developed hives. At the time of the report, the outcome of the patient was unknown. No product quality complaint was involved. Follow up information received from the patient and she reported that she didn't remembered the name because it has been several years since and she didn't know how to contact or if still in business (physician was elderly). Additional information is not expected.
Dizziness,chest pain, numbness, palpitation,low blood pressure and heart rate, resolved in 1 hour. Dizziness and numbness persisting.
Shingles lesions, diagnosed with shingles; Shingles lesions, diagnosed with shingles; backache, thought it was a pulled muscle; thought it was a pulled muscle; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 06-MAR-2023, the patient received the 1st dose of Shingrix (intramuscular). On 11-MAR-2023, 5 days after receiving Shingrix, the patient experienced back pain (Verbatim: backache, thought it was a pulled muscle) and pulled muscle (Verbatim: thought it was a pulled muscle). On 12-MAR-2023, the patient experienced shingles (Verbatim: Shingles lesions, diagnosed with shingles) and skin lesion (Verbatim: Shingles lesions, diagnosed with shingles). The outcome of the shingles, skin lesion, back pain and pulled muscle were not recovered/not resolved.   It was unknown if the reporter considered the shingles, skin lesion, back pain and pulled muscle to be related to Shingrix.     It was unknown if the company considered the shingles, skin lesion, back pain and pulled muscle to be related to Shingrix.   Additional Information: GSK receipt date: 16-Mar-2023 The patient who received her first dose of Shingirx and 5 days after vaccination, in the evening, she began having a backache and  thought it was a pulled muscle.   The next day she had the Shingles lesions. On 14th March 2023, the patient was diagnosed with full-blown shingles by her physician. The batch number was unknown but should be able to access it by contacting the pharmacy, which was entered in the vaccine facility details fields.  The reporter gave consent to contact her physician.
Recurring bright red blood in stool. Moderate and persistent abdominal pain.    Apparent sudden onset GI allergy to dairy and soy, symptoms subside 3-4 days following food elimination   Potential eosinophilic colitis ?   No prior history
Non Small Cell adenocarcinoma lung, EGFR exon 20 +, MSS, TMB low, PD-L1 negative, veristrat good Stage IV, treated initially with 4 cycles carboplatin + pemetrexed + pembrolizumab Current treatment with amivantimab
Hands & feet numb, can hardly walk.  Admitted to hospital.  ?Guillain Barre  ?if from influenza vaccine. records received 3/5/08-for DOS 2/5-2/12/08. DC DX:Guillain-Barre syndrome. Seconardy diagnoses:Pregnancy 19 weeks, tachycardia associated with previous pregnancies.  Presented with progressive ascending numbness and tingling which she had been experiencing over the past four weeks. Nausea and vomiting about a week prior to development of symptoms. Symptoms began in feet with numbness and tingling over the course of the day progressed to hands. Tingling tip of nose the following week. Weakness bilaterally in lower extremities and difficulty walking because of weakness. Fatigue with exertion and walking. Headaches experiencing throughout pregnancy. Treated with IVIG with improvment and susequent discharge. Follow-up: Still has some residual side effects, weakness, loss of stamina, loss of strength pain in legs, arms, hands and feet.
A vaccine was given that experienced a temperature excursion. The affected vial was in the freezer past the 2 weeks of stability info provided by the CDC.
Information has been received from a consumer concerning a her approximately 12 month old son with pertinent medical history reported as none and drug reactions or allergies reported as none who on an unspecified date was vaccinated with a first dose of MMR II (lot # not reported). The vaccine was expired. The patient was to return "several weeks" later to be revaccinated but the dose was postponed since the child had an ear infection. On 29-JUN-2009 he received second dose of MMR II (lot # not reported). There was no concomitant medication. After received the second dose of vaccine the patient developed fever, rash, watery eye and watery runny nose. "He was really sick". The child was seen in the emergency room. The mother stated she was told be the emergency room "he had a viral infection" and he was discharged home with his mother. At the time on the report on 06-JUL-2009 the patient had not recovered. Follow up information has been received from a nurse and medical record concerning a 17 month old patient with pertinent medical history reported as none, drug allergies reported as none and illness at the time of vaccination report as none. On 05-JUL-2009 the patient experienced fever over 102 degrees, cough and no oral intake was taken by his mother to the Emergency Room. The patient had been afebrile and did not received any TYLENOL and his temperature was 37.4 degrees. About 7 days prior to presentation to the Emergency Room, patient received MMR II at his doctor's office. The patient had not been himself according to the mother and had had decreased appetite, however, no vomiting or diarrhea reported. Patient had no sick contacts. The patient was followed by the physician. The patient also had sudden onset of rash involving the neck and torso. That was the reason why mom got the emergency room despite the patient being afebrile. The patient was doing well and had adequate urine output. The patient presented to upset Emergency Room for evaluation and management. In the Emergency Room physical examination was performed: weight: 12.35 kilos, blood pressure: 82/palp, heart rate: 122, respiratory rate: 24, saturation: 99%, temperature: 37.4 degrees. General appearance: Well-appearing kid, not sick at all, not in acute distress. Heent: Mild nasal congestion, clear tympanic membranes, clear throat. Chest: Bilateral equal air entry clear. Heart: S1, S2 normal, no murmur. Abdomen; Soft, nontender, no hepatosplenomegaly. Pulses: 2+, well perfused. Capillary refill less than 2 seconds. Musculoskeletal: No issues. Skin: Morbilliform rash blanching over the neck and trunk, front and back. The patient was diagnosed by physician with viral syndrome. The patient was found well hydrated. The patient tolerated apple juice in the Emergency Room. The patient will be discharged home in good condition with diet regular, activity as tolerated, TYLENOL as need for fever. Follow up with the primary care physician in one day. According to the father the patient recovered on 06-JUL-2009. Additional information is not expected.